News from QAdvis

ISO 10993-1, the core standard for the biological evaluation of medical devices, has been under revision over the past few years. A Final Draft International Standard (FDIS) was published earlier this spring, and the voting was closed the July 17. The standard was approved and is now under publication. What’s changing? The new version of […]

Post-Market Surveillance (PMS) is more than complaint handling – it’s a strategic tool for patient safety, regulatory compliance, and continuous improvement. Under the EU MDR, a structured, proactive approach with strong links to risk management and authority dialogue is essential. PMS has become a cornerstone of regulatory work under EU MDR 2017/745 and IVDR 2017/746. […]

In the competitive and highly regulated world of medical technology, a robust and well-structured Design and Development (D&D) process is not just a best practice—it is a business-critical necessity. From concept to commercialization, a robust D&D process lays the foundation for safety, compliance, efficiency, and innovation. Below, we explore why medical device companies must prioritize […]

Tough times require sharp strategies – and the right expertise The industry’s financing climate has slowed down considerably. Investments in the development of pharmaceuticals and medtech are more cautious, and Ulrika Hammarström, Head of CRO at Aurevia, emphasizes that the requirements for a clear market and regulatory strategy have never been higher. For pharmaceutical, biotech […]

Navigating the regulatory landscape of the medical device sector is a complex task, requiring both strategic foresight and a deep understanding of evolving global requirements. Companies must not only ensure compliance with current regulations but also anticipate changes that could impact product development, market access, and post-market obligations. Within this context, two distinct but closely […]